Risk stratification and medical therapy of pulmonary arterial hypertension
暂无分享,去创建一个
Z. Jing | V. McLaughlin | E. Grünig | R. Frantz | O. Moiseeva | T. Pulido | N. Galiè | I. Preston | R. Channick | Y. Tamura | Z. Safdar | Y. Tamura | Yuichi Tamura
[1] P. Corris,et al. Intensive care, right ventricular support and lung transplantation in patients with pulmonary hypertension , 2019, European Respiratory Journal.
[2] J. Lumens,et al. Pathophysiology of the right ventricle and of the pulmonary circulation in pulmonary hypertension: an update , 2019, European Respiratory Journal.
[3] M. Humbert,et al. Pathology and pathobiology of pulmonary hypertension: state of the art and research perspectives , 2019, European Respiratory Journal.
[4] Paul G. Williams,et al. Haemodynamic definitions and updated clinical classification of pulmonary hypertension , 2019, European Respiratory Journal.
[5] S. Söderberg,et al. A comprehensive risk stratification at early follow-up determines prognosis in pulmonary arterial hypertension , 2018, European heart journal.
[6] M. Humbert,et al. Validation of a risk assessment instrument for pulmonary arterial hypertension , 2018, European heart journal.
[7] E. Zuffa,et al. P4538Simplified table for risk stratification in patients with different types of pulmonary arterial hypertension , 2018, European Heart Journal.
[8] R. Benza,et al. Baseline and Serial Brain Natriuretic Peptide Level Predicts 5‐Year Overall Survival in Patients With Pulmonary Arterial Hypertension: Data From the REVEAL Registry , 2018, Chest.
[9] M. Humbert,et al. Risk assessment in pulmonary arterial hypertension , 2018, European Respiratory Journal.
[10] A. Torbicki,et al. Pulmonary Arterial Hypertension-Related Morbidity Is Prognostic for Mortality. , 2018, Journal of the American College of Cardiology.
[11] R. Benza,et al. Impact of declining renal function on outcomes in pulmonary arterial hypertension: A REVEAL registry analysis. , 2018, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.
[12] S. Rosenkranz,et al. RESPITE: switching to riociguat in pulmonary arterial hypertension patients with inadequate response to phosphodiesterase-5 inhibitors , 2017, European Respiratory Journal.
[13] M. Humbert,et al. Risk assessment, prognosis and guideline implementation in pulmonary arterial hypertension , 2017, European Respiratory Journal.
[14] S. Rosenkranz,et al. Mortality in pulmonary arterial hypertension: prediction by the 2015 European pulmonary hypertension guidelines risk stratification model , 2017, European Respiratory Journal.
[15] S. Ulrich,et al. Rehabilitation in patients with pulmonary arterial hypertension. , 2017, Swiss medical weekly.
[16] V. Russo,et al. Left Main Coronary Artery Compression in Patients With Pulmonary Arterial Hypertension and Angina. , 2017, Journal of the American College of Cardiology.
[17] J. Wirth,et al. A systematic review of transition studies of pulmonary arterial hypertension specific medications , 2017, Pulmonary circulation.
[18] A. Torbicki,et al. SERAPHIN haemodynamic substudy: the effect of the dual endothelin receptor antagonist macitentan on haemodynamic parameters and NT-proBNP levels and their association with disease progression in patients with pulmonary arterial hypertension , 2017, European heart journal.
[19] Y. Lacasse,et al. Combination therapy versus monotherapy for pulmonary arterial hypertension: a meta-analysis. , 2016, The Lancet. Respiratory medicine.
[20] M. Humbert,et al. Initial dual oral combination therapy in pulmonary arterial hypertension , 2016, European Respiratory Journal.
[21] W. Seeger,et al. Exercise training improves peak oxygen consumption and haemodynamics in patients with severe pulmonary arterial hypertension and inoperable chronic thrombo-embolic pulmonary hypertension: a prospective, randomized, controlled trial , 2015, European heart journal.
[22] Stefan L. Zimmerman,et al. Ambrisentan and Tadalafil Up-front Combination Therapy in Scleroderma-associated Pulmonary Arterial Hypertension. , 2015, American journal of respiratory and critical care medicine.
[23] R. Benza,et al. Five-Year outcomes of patients enrolled in the REVEAL Registry. , 2015, Chest.
[24] Simon Gibbs,et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension , 2015, European Respiratory Journal.
[25] J. Barberà,et al. Initial Use of Ambrisentan plus Tadalafil in Pulmonary Arterial Hypertension. , 2015, The New England journal of medicine.
[26] H. Ghofrani,et al. Bosentan added to sildenafil therapy in patients with pulmonary arterial hypertension , 2015, European Respiratory Journal.
[27] M. Humbert,et al. Validation of two predictive models for survival in pulmonary arterial hypertension , 2015, European Respiratory Journal.
[28] R. Benza,et al. Prognostic implications of serial risk score assessments in patients with pulmonary arterial hypertension: a Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL) analysis. , 2015, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.
[29] E. Grünig,et al. PATENT PLUS: a blinded, randomised and extension study of riociguat plus sildenafil in pulmonary arterial hypertension , 2015, European Respiratory Journal.
[30] H. Ghofrani,et al. Selexipag for the Treatment of Pulmonary Arterial Hypertension. , 2014, The New England journal of medicine.
[31] E. Grünig,et al. PATENT PLUS: a blinded, randomised and extension study of riociguat plus sildenafil in PAH , 2015 .
[32] Simon Gibbs,et al. [2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension]. , 2015, Kardiologia polska.
[33] Y. Zhuang,et al. Randomized study of adding tadalafil to existing ambrisentan in pulmonary arterial hypertension , 2014, Hypertension Research.
[34] M. Pritzker,et al. Performance of the REVEAL pulmonary arterial hypertension prediction model using non-invasive and routinely measured parameters. , 2014, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.
[35] W. Seeger,et al. Algorithm of Pulmonary Arterial Hypertension , 2022 .
[36] R. Benza,et al. Evaluation of the predictive value of a clinical worsening definition using 2-year outcomes in patients with pulmonary arterial hypertension: a REVEAL Registry analysis. , 2013, Chest.
[37] Z. Jing,et al. Macitentan and morbidity and mortality in pulmonary arterial hypertension. , 2013, The New England journal of medicine.
[38] M. Humbert,et al. Riociguat for the treatment of pulmonary arterial hypertension. , 2013, The New England journal of medicine.
[39] H. Ghofrani,et al. Imatinib Mesylate as Add-on Therapy for Pulmonary Arterial Hypertension: Results of the Randomized IMPRES Study , 2013, Circulation.
[40] Z. Jing,et al. Efficacy and Safety of Oral Treprostinil Monotherapy for the Treatment of Pulmonary Arterial Hypertension: A Randomized, Controlled Trial , 2013, Circulation.
[41] Z. Jing,et al. Oral treprostinil for the treatment of pulmonary arterial hypertension in patients receiving background endothelin receptor antagonist and phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C2 study): a randomized controlled trial. , 2013, Chest.
[42] D. Badesch,et al. Oral treprostinil for the treatment of pulmonary arterial hypertension in patients on background endothelin receptor antagonist and/or phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C study): a randomized controlled trial. , 2012, Chest.
[43] T. Fleming,et al. Biomarkers and surrogate endpoints in clinical trials , 2012, Statistics in medicine.
[44] A. Peacock,et al. Predicting survival in pulmonary arterial hypertension in the UK , 2012, European Respiratory Journal.
[45] M. Gomberg-Maitland,et al. Validation of the pulmonary hypertension connection equation for survival prediction in pulmonary arterial hypertension. , 2012, Chest.
[46] A. Torbicki,et al. Selexipag: an oral, selective prostacyclin receptor agonist for the treatment of pulmonary arterial hypertension , 2012, European Respiratory Journal.
[47] R. Benza,et al. The REVEAL Registry risk score calculator in patients newly diagnosed with pulmonary arterial hypertension. , 2012, Chest.
[48] Z. Jing,et al. Vardenafil in pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled study. , 2011, American journal of respiratory and critical care medicine.
[49] M. Mcgoon,et al. Integration of clinical and hemodynamic parameters in the prediction of long-term survival in patients with pulmonary arterial hypertension. , 2011, Chest.
[50] H. Ghofrani,et al. Imatinib in pulmonary arterial hypertension patients with inadequate response to established therapy. , 2010, American journal of respiratory and critical care medicine.
[51] Christopher S Coffey,et al. Predicting Survival in Pulmonary Arterial Hypertension: Insights From the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL) , 2010, Circulation.
[52] M. Humbert,et al. Survival in incident and prevalent cohorts of patients with pulmonary arterial hypertension , 2010, European Respiratory Journal.
[53] A. Manes,et al. Pulmonary arterial hypertension: from the kingdom of the near-dead to multiple clinical trial meta-analyses , 2010, European heart journal.
[54] Horst Olschewski,et al. Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: a randomized controlled clinical trial. , 2010, Journal of the American College of Cardiology.
[55] K. Iversen,et al. Combination therapy with bosentan and sildenafil in Eisenmenger syndrome: a randomized, placebo-controlled, double-blinded trial. , 2010, European heart journal.
[56] M. Humbert,et al. Survival in Patients With Idiopathic, Familial, and Anorexigen-Associated Pulmonary Arterial Hypertension in the Modern Management Era , 2010, Circulation.
[57] Sanjiv J. Shah,et al. Contemporary Survival in Patients with Pulmonary Arterial Hypertension: A Reappraisal of the National Institutes of Health Risk Stratification Equation , 2009 .
[58] B. Brundage,et al. Tadalafil Therapy for Pulmonary Arterial Hypertension , 2009, Circulation.
[59] A. Branzi,et al. A meta-analysis of randomized controlled trials in pulmonary arterial hypertension , 2008, European heart journal.
[60] D. Badesch,et al. Ambrisentan therapy in patients with pulmonary arterial hypertension who discontinued bosentan or sitaxsentan due to liver function test abnormalities. , 2006, Chest.
[61] T. Fleming,et al. End points and clinical trial design in pulmonary arterial hypertension. , 2004, Journal of the American College of Cardiology.
[62] T. Fleming,et al. Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: a randomized trial. , 2008, Annals of internal medicine.
[63] G. Simonneau,et al. Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial , 2008, The Lancet.
[64] B. Wiens,et al. Ambrisentan for the Treatment of Pulmonary Arterial Hypertension: Results of the Ambrisentan in Pulmonary Arterial Hypertension, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Efficacy (ARIES) Study 1 and 2 , 2008, Circulation.
[65] E. Hachulla. Effects of Beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension : a randomized, double-blind, placebo-controlled trial. , 2008 .
[66] R. Barst,et al. Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension. , 2006, American journal of respiratory and critical care medicine.
[67] M. Hoeper,et al. Combining inhaled iloprost with bosentan in patients with idiopathic pulmonary arterial hypertension , 2006, European Respiratory Journal.
[68] M. Gatzoulis,et al. Bosentan Therapy in Patients With Eisenmenger Syndrome: A Multicenter, Double-Blind, Randomized, Placebo-Controlled Study , 2006, Circulation.
[69] R. Barst,et al. Treatment of pulmonary arterial hypertension with the selective endothelin-A receptor antagonist sitaxsentan. , 2006, Journal of the American College of Cardiology.
[70] S. Malhotra,et al. A randomized, placebo-controlled, double-blind, crossover study to evaluate the efficacy of oral sildenafil therapy in severe pulmonary artery hypertension. , 2006, American heart journal.
[71] T. Fleming,et al. Sildenafil citrate therapy for pulmonary arterial hypertension. , 2005, The New England journal of medicine.
[72] D. Pennell,et al. Sildenafil versus Endothelin Receptor Antagonist for Pulmonary Hypertension (SERAPH) study. , 2005, American journal of respiratory and critical care medicine.
[73] Thomas R Fleming,et al. Surrogate endpoints and FDA's accelerated approval process. , 2005, Health affairs.
[74] M. Humbert,et al. Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2 , 2004, European Respiratory Journal.
[75] W. Seeger,et al. Comparative analysis of clinical trials and evidence-based treatment algorithm in pulmonary arterial hypertension. , 2004, Journal of the American College of Cardiology.
[76] B. Raju,et al. Clinical efficacy of sildenafil in primary pulmonary hypertension: a randomized, placebo-controlled, double-blind, crossover study. , 2004, Journal of the American College of Cardiology.
[77] R. Dixon,et al. Sitaxsentan therapy for pulmonary arterial hypertension. , 2004, American journal of respiratory and critical care medicine.
[78] K. Wasserman,et al. Beraprost therapy for pulmonary arterial hypertension. , 2003, Journal of the American College of Cardiology.
[79] W. Seeger,et al. Inhaled iloprost for severe pulmonary hypertension. , 2002, The New England journal of medicine.
[80] W. Seeger,et al. Effects of the thromboxane synthetase inhibitor and receptor antagonist terbogrel in patients with primary pulmonary hypertension. , 2002, American heart journal.
[81] M. Humbert,et al. Effects of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled trial. , 2002, Journal of the American College of Cardiology.
[82] Bosentan therapy for pulmonary arterial hypertension. , 2002, The New England journal of medicine.
[83] S. Rich,et al. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. , 2002, American journal of respiratory and critical care medicine.
[84] D. Badesch,et al. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebocontrolled study , 2001, The Lancet.
[85] Stuart Rich,et al. Continuous Intravenous Epoprostenol for Pulmonary Hypertension Due to the Scleroderma Spectrum of Disease , 2000, Annals of Internal Medicine.
[86] Inda,et al. A COMPARISON OF CONTINUOUS INTRAVENOUS EPOPROSTENOL ( PROSTACYCLIN ) WITH CONVENTIONAL THERAPY FOR PRIMARY PULMONARY HYPERTENSION , 2000 .
[87] B. Groves,et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. , 1996, The New England journal of medicine.
[88] E H Bergofsky,et al. Survival in Patients with Primary Pulmonary Hypertension: Results from a National Prospective Registry , 1991 .
[89] J. H. Diehl,et al. Treatment of Primary Pulmonary Hypertension with Continuous Intravenous Prostacyclin (Epoprostenol): Results of a Randomized Trial , 1990 .